



Assessing TB Treatment Facility Distribution and Accessibility in Akwa Ibom State, Nigeria

Dohyo Jeong
University of Texas at Dallas

Contents



Introduction



Frameworks



Results







Conclusion

Introduction

Introduction



-  Nigeria is one of the largest and most populous countries in Africa.
-  Nigeria is ranked seventh among the countries with the highest risk of tuberculosis by WHO (Ogbudebe et al., 2023).
-  Various international organizations are implementing aid and policies for tuberculosis treatment and prevention (Erah & Ojieabu, 2009).
-  However, ***Nigeria's tuberculosis problem is still unresolved*** (Asuquo et al., 2015; Ibokette et al., 2022; Ogbudebe et al., 2023).

Introduction

Introduction



- ▶ Numerous studies have examined non-adherence to TB treatment in Nigeria (Oga-Omenka et al., 2021; Sullivan et al., 2017; Babatunde et al., 2015).
- ▶ However, ***research investigating TB treatment with accessibility among TB patients in high-burden regions of Nigeria has been limited.***
- ▶ This study utilizes GIS raster analysis to ***investigate the accessibility of treatment facilities and the distribution of TB patients in Akwa Ibom State***, shedding light on this complexity and elucidating how regional differences in accessibility impact TB treatment compliance.

TB Wards in Nigeria's Healthcare System

- ▶ ***Provide diagnosis and initial treatment for TB.***
- ▶ Crucial for early detection and prevention of disease spread.
- ▶ Monitor and support patients throughout treatment.
- ▶ Conduct TB prevention education and outreach in communities (Ogbudebe et al., 2023).
- ▶ Challenges:
 - ***Accessibility issues*** (Oga-Omenka et al., 2021).
 - ***Distance and transportation barriers.***
 - Increased risk of ***treatment interruption*** or ***non-initiation*** (Sullivan et al., 2017).
 - Shortages of medical personnel and equipment (Babatunde et al., 2015).
 - Difficulty in diagnosis, treatment, and patient monitoring.

Challenges in TB Management in Nigeria

▶ Demographic Disparities in TB Treatment:

- ***Certain groups delay or forgo treatment post-diagnosis*** (Ogbuabor & Onwujekwe, 2019).
- Influenced by gender, age, occupation, education, and religion (Sariem et al., 2020).

▶ Accessibility Issues:

- ***Uneven patient distribution*** despite even TB ward distribution (Oga-Omenka et al., 2020; Ogbudebe et al., 2023).
- Concentration of cases in specific regions (Sullivan et al., 2017).

▶ High TB Incidence Areas:

- ***Increased travel distances and costs for patients.***
- Difficulty in maintaining treatment adherence.

Challenges in TB Management in Nigeria

► Study Focus:

- *Emphasizes individual facility accessibility.*
- Importance of access for all, irrespective of location or socio-economic status.
- Special attention to *densely populated, high-prevalence areas.*

► Addressing Barriers:


- Essential for reducing TB burden.
- Tailored efforts for demographic groups and accessibility improvement needed.

Research Design

Research Design


- Research Area: **Akwa Ibom State, Nigeria.**
- Time scope: **October 2020 ~ January 2022**
- Data Resource:
 - ▶ **KNCV Nigeria Tuberculosis Foundation**
- *Focus on accessibility rather than capacity.*
- **LRR** illustrates the supply and demand pattern and the degree of imbalance.
- **Spatial Statistics** estimates the impact of an imbalance of supply and demand on TB treatment.
- **Location-Allocation** statistically finds the optimal TB ward location.

Research Flow




Research Design

Research Area



- **Akwa Ibom:** A hotspot for tuberculosis in Southern Nigeria (Ogbudebe et al., 2023)

Population Density




Results

Demographics of Tuberculosis Treatment Facility Demand

	TB Test cases	TB Positive cases	TB Treatment started	TB Treatment Did NOT started	Date until treatment starts
	#	# (row %)	# (row %)	# (row %)	Median date
Total	8638	1612(18.66%)	1401(86.91%)	211(13.09%)	2
Gender					
Male	3693	926(25.07%)	818(88.34%)	108(11.06%)	1
Female	4645	686(14.77%)	583(84.99%)	103(15.01%)	2
Age					
0~9	633	48(7.58%)	41(85.42%)	7(14.58%)	3
10~19	586	118(20.14%)	105(88.98%)	13(11.02%)	3.5
20~29	1310	308(23.51%)	276(89.61%)	32(10.39%)	1
30~39	1837	435(23.68%)	376(86.44%)	59(13.56%)	1
40~49	1446	330(22.82%)	288(87.27%)	42(12.73%)	1
50~59	1124	184(16.37%)	162(88.04%)	22(11.96%)	3
60~69	1038	124(11.95%)	100(80.65%)	24(19.35%)	2
70 and over	664	65(9.79%)	53(81.54%)	12(18.46%)	1

Data and Variables

TB Wards Distribution





- **Evenly spread** along major roads for accessible TB treatment.
- **Uniform distribution aims for equitable service** to all residents.
- **Theoretical benefits:** Fairer healthcare, prevents regional discrimination in TB care.
- **Challenges:** **Inefficiencies in areas with concentrated TB demand**; risk of overloading and service delays in high-incidence regions.

► **Let's look at the demand distribution.**

Results

TB patients Distributions



Suspected TB patients



Results

TB patients Distributions



Confirmed TB cases



Results

TB patients Distributions


Not Treatment for TB cases



Results


Kernel Density

Bandwidth 10km




under-smoothing

Bandwidth 20km



Bandwidth 30km




over-smoothing

Results


Kernel Density

Bandwidth 10km




under-smoothing

Bandwidth 20km



Bandwidth 30km



over-smoothing

Log Relative Risk with Kernel Density

Log Relative Risk

$$\log(\text{relative risk}(\mathbf{s})) = \log\left(\frac{\lambda^{\text{demand}}(\mathbf{s})}{\lambda^{\text{supply}}(\mathbf{s})}\right)$$

\mathbf{s} : Surface (area) of a specific county

$\lambda^{\text{supply}}(\mathbf{s})$: Supply density of TB wards on surface based on kernel density


$\lambda^{\text{demand}}(\mathbf{s})$: Demand density of TB patients on surface based on kernel density

$$LRR \begin{cases} > 0: \text{Under Supply} \\ = 0: \text{Balanced} \\ < 0: \text{Over Supply} \end{cases}$$


Results

Log Relative Risk with Kernel Density

Log Relative Risk of *Suspected TB cases*



Log Relative Risk of *Confirmed TB cases*



Results

Impact of accessibility on TB treatment

Results of Spatial Logistic Regression for TB treatment start

Treatment = 1
 Not treatment = 0
 Male = 0
 Female = 1

logit	Model 1		Model 2		Model 3	
	Coeff (Std.Err)	z	Coeff (Std.Err)	z	Coeff (Std.Err)	Z
_cons	-0.471 (0.331)	-1.42	-1.055 (0.392)	-2.69***	-0.490 (0.986)	-0.50
LRR	-1.497 (0.344)	-4.35***	-1.482 (0.346)	-4.28***	-2.112 (1.035)	-2.04**
Gender			-0.312 (0.151)	-2.06**	-1.602 (0.686)	-2.33**
Age			-0.011 (0.004)	-2.37**	-0.018 (0.021)	-0.85
LRR*Gender					2.041 (0.712)	2.87***
LRR*Age					0.007 (0.022)	0.33
Obs	1602		1602		1602	
Pseudo R ²	0.014		0.021		0.028	
Log likelihood	-607.606		-603.242		-598.906	

*** p<0.01, ** p<0.05, * p<0.1

- As the Log Relative Risk (LRR) increases (indicating an increase in supply shortage), the probability of not receiving treatment also increases.
- It was found that women were more likely not to receive treatment than men.
- As LRR increased, differences in treatment by gender became more pronounced.

Results

Impact of accessibility on TB treatment

Results of Cox Regression for TB Treatment Starting Date

Treatment = 1
 Not treatment = 0
 Male = 0
 Female = 1


Treatment Ratio	Model 1		Model 2		Model 3	
	Haz.ratio (Std.Err)	z	Haz.ratio (Std.Err)	z	Haz.ratio (Std.Err)	Z
LRR	-1.612 (0.293)	-2.63***	-1.650 (0.301)	-2.74***	-5.142 (2.818)	-2.99***
Gender			-0.886 (0.059)	-1.79*	-1.989 (0.733)	-1.86*
Age			-0.998 (0.002)	-0.62	-1.018 (0.011)	-1.60
LRR*Gender					-0.434 (0.163)	-2.22**
LRR*Age					-0.980 (0.011)	-1.73
Obs	1127		1127		1127	
X ²	7.19		10.53		16.97	
Log likelihood	-5783.515		-5781.846		-5778.623	

*** p<0.01, ** p<0.05, * p<0.1

- For each unit increase in LRR, the time required to initiate treatment increases by a factor of 5.142.
- Women need 1.989 times more time to start treatment compared to men.
- The increase in LRR significantly amplifies the difference in treatment initiation between men and women.

Results

Risk Area of TB cases in Akwa Ibom



- **Zone 1 (High-High)** faces significant challenges in both access to testing and treatment due to the high density of suspected and confirmed cases.
- **Zone 2 (Low-High)** competition for testing services is reduced, allowing quicker diagnoses. However, patients in Zone 2 experience relatively poor accessibility to treatment services due to the high density of confirmed cases.
- **Zone 3 (High-Low)** faces challenges in accessing diagnostic services due to the high density of suspected cases and potential supply shortages.
- **Zone 4 (Low-Low)**, patients have relatively good accessibility to testing and treatment compared to other regions.

► **How can we alleviate these imbalances at minimal cost?**

Results

Location-Allocation

Potential *Optimal New TB Ward* Location based on *P-median*

$$\text{Minimize } \sum_{i \in I} \sum_{j \in J} a_{ij} d_{ij} x_{ij}$$

$$\text{subject to } \sum_{i \in I} x_{ij} = 1 \quad \text{for } j \in J$$

$$x_{ij} \leq y_j \quad \text{for } i \in I, j \in J$$

$$\sum_{i \in I} y_j = p$$

$$x_{ij}, y_j \in \{0, 1\} \quad \text{for } i \in I, j \in J$$

i : points of demand;


j : points of the potential TB ward site;

a_{ij} : number of total demand in the service area;

d_{ij} : the minimum travel distance that the patient is required to travel from point i ;

$$x_{ij} = \begin{cases} 1 & \text{if demand } i \text{ is assigned to TB ward at location } j \\ 0 & \text{otherwise} \end{cases}$$


$$y_j = \begin{cases} 1 & \text{if TB ward is sited at location } j \\ 0 & \text{otherwise} \end{cases}$$



Results

Location-Allocation

Potential *Optimal New TB Ward* Location based on *P-median*



- **Optimal Location Allocation:** Ensures TB wards are strategically placed for *maximum accessibility*.
- **Enhanced Accessibility:** Reduces patient travel time and distance, *promoting better healthcare access*.
- **Targeted Impact:** *Focuses on high-need areas*, ensuring that TB wards are located where they are most needed.
- **Cost-Effective:** *Minimizes operational costs* by selecting locations that effectively serve the most patients.

Conclusion

Discussion and Conclusion

- ▶ This study **highlights the distribution of tuberculosis treatment facilities** across Akwa Ibom State, emphasizing the importance of tuberculosis medical accessibility.
- ▶ The study results **support the concept of demographic barriers to tuberculosis treatment initiation and timing**, as previously indicated in other studies (Sariem et al., 2020; Oga-Omenka et al., 2020; Oga-Omenka et al., 2021).
- ▶ The analysis underscores gender disparities in tuberculosis treatment initiation timing, with **women experiencing longer delays compared to men**.
- ▶ Potential relative risk areas and **optimal ward locations were explored through p-median**.
- ▶ This study **focuses only on accessibility rather than the capacity of the ward**. In future research, it is **necessary to explore more sophisticated risk areas by weighting the capacity of each ward**.
- ▶ It did **not reflect the ward's accessibility to areas surrounding and bordering the Akwa Ibom government**.

Key References

- Adepoju, V. A., Oladimeji, O., Sibiya, M. N., Inegbeboh, J., & Egesemba, G. (2023). Tuberculosis management and referral practices among traditional medicine practitioners in Lagos, Nigeria. *Journal of Public Health in Africa*, 14(2).
- Adepoju, V. A., Oladimeji, O., Sibiya, M. N., Inegbeboh, J., & Egesemba, G. (2023). Tuberculosis management and referral practices among traditional medicine practitioners in Lagos, Nigeria. *Journal of Public Health in Africa*, 14(2).
- Bassey, A., Antia, E., & Usoroh E. (2021). PREVALENCE AND OUTCOMES OF MULTI DRUG RESISTANT TUBERCULOSIS IN AKWA IBOM STATE NIGERIA: A RETROSPECTIVE STUDY. *World*, 13(1), 10-18.
- Oga-Omenka, C., Bada, F., Agbaje, A., Dakum, P., Menzies, D., & Zarowsky, C. (2020). Ease and equity of access to free DR-TB services in Nigeria-a qualitative analysis of policies, structures and processes. *International Journal for Equity in Health*, 19, 1-13.
- Oga-Omenka, C., Boffa, J., Kuye, J., Dakum, P., Menzies, D., & Zarowsky, C. (2020). Understanding the gaps in DR-TB care cascade in Nigeria: A sequential mixed-method study. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, 21, 100193.
- Oga-Omenka, C., Wakdet, L., Menzies, D., & Zarowsky, C. (2021). A qualitative meta-synthesis of facilitators and barriers to tuberculosis diagnosis and treatment in Nigeria. *BMC Public Health*, 21, 1-12.
- Oga-Omenka, C., Zarowsky, C., Agbaje, A., Kuye, J., & Menzies, D. (2019). Rates and timeliness of treatment initiation among drug-resistant tuberculosis patients in Nigeria-A retrospective cohort study. *PloS one*, 14(4), e0215542.
- Ogbuabor, D. C., & Onwujekwe, O. E. (2019). Governance of tuberculosis control programme in Nigeria. *Infectious diseases of poverty*, 8, 1-11.
- Ogbudebe, C., Jeong, D., Odume, B., Chukwuogo, O., Dim, C., Useni, S., ... & Gidado, M. (2023). Identifying Hot Spots of Tuberculosis in Nigeria Using an Early Warning Outbreak Recognition System: Retrospective Analysis of Implications for Active Case Finding Interventions. *JMIR Public Health and Surveillance*, 9(1), e40311.
- Olayanju, O., Otaigbe, I., Sodeinde, K., Abiodun, O., & Adebisi, A. (2023). Factors associated with delay of patients with cough to tuberculosis treatment centres in selected DOTS in South-West Nigeria. *Indian Journal of Tuberculosis*.
- Sariem, C. N., Odumosu, P., Dapar, M. P., Musa, J., Ibrahim, L., & Aguiyi, J. (2020). Tuberculosis treatment outcomes: a fifteen-year retrospective study in Jos-North and Mangu, Plateau State, North-Central Nigeria. *BMC Public Health*, 20, 1-11.
- Sullivan, B. J., Esmaili, B. E., & Cunningham, C. K. (2017). Barriers to initiating tuberculosis treatment in sub-Saharan Africa: a systematic review focused on children and youth. *Global health action*, 10(1), 1290317.